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 OESOPHAGUS
Chromosome 4 hyperploidy represents an early genetic
aberration in premalignant Barrett’s oesophagus
S H Doak, G J S Jenkins, E M Parry, F R D’Souza, A P Griffiths, N Toffazal, V Shah,
J N Baxter, J M Parry
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Background and aims: Characterisation of the underlying molecular mechanisms that promote Bar-
rett’s progression may ultimately lead to identification of potential predictive genetic markers that clas-
sify patients’ malignant risk. In an attempt to understand these causative pathways, fluorescence in situ
hybridisation (FISH) was used in this study to determine when specific genetic alterations arise during
Barrett’s associated neoplastic progression.
Methods: Endoscopic cytology brushings were obtained from 28 patients with Barrett’s metaplasia,
28 with dysplasia (20 low grade dysplasia (LGD) and eight with high grade dysplasia (HGD)), and
seven with adenocarcinoma, together with paired control brushings from regions of normal proximal
squamous cell epithelium. The exfoliated epithelial cells were washed and deposited onto slides.
Probes specific for the centromeres of chromosomes 4, 8, 20, and Y, and locus specific probes for the
tumour suppressor genes p16, p53, and Rb were subsequently hybridised.
Results: Aneuploidy was found early in progression, with metaplastic tissues displaying increased
copy numbers of chromosomes 4 and 8. Chromosome 4 hyperploidy was found in 89%, 90%, 88%,
and 100% of metaplasias, LGD, HGD, adenocarcinomas, respectively, while chromosome 8
hyperploidy occurred in 71%, 75%, 100%, and 100% of patients with the respective staging. Loss of
the p16 tumour suppressor gene also presented in metaplastic epithelium (7%) but most other genetic
aberrations were only seen in HGD.
Conclusions: Genetic instability arises well before dysplasia in Barrett’s oesophagus, with
chromosome 4 and 8 hyperploidy representing the earliest and most common alterations identified. As
these aberrations are widespread at all the premalignant stages, there may be genes on chromosomes
4 and 8 that are involved in both the initiation and progression of Barrett’s oesophagus.
Barrett’s oesophagus is a premalignant lesion that isstrongly associated with chronic gastro-oesophagealreflux1 and has recently been defined as the presence of
any length of columnar epithelia containing goblet cells
within the distal oesophagus.2 The condition predisposes
patients to oesophageal adenocarcinoma, however, due to self
treatment for heartburn and diminished sensitivity of the
columnar mucosa to refluxed acid, such adenocarcinomas are
often only diagnosed at an advanced stage. The incidence of
this malignancy is rapidly rising in the USA and Western
Europe, currently varying from 3.2 to 5.2 cases/100 000/year3–5
and is reputed to be very aggressive due to both early invasion
and metastasis, which consequently result in low five year
survival rates of just 10%.6
Barrett’s metaplasia is known to progress through low
grade dysplasia (LGD) and high grade dysplasia (HGD) prior
to adenocarcinoma but the underlying molecular mechanisms
involved in Barrett’s neoplastic progression are still unclear.
Genetic abnormalities involving a variety of oncogenes,
tumour suppressor genes, cell adhesion molecules, and
growth factors have been identified7–9 but the functional
involvement of these alterations in driving tumorigenesis has
yet to be defined.
Currently, endoscopic surveillance coupled with his-
topathological evaluation for dysplasia remains the “gold
standard” for assessing the neoplastic potential of Barrett’s
oesophagus (with HGD employed as the marker for subse-
quent adenocarcinoma development). Unfortunately, several
problems exist with this current regimen. Firstly, the progres-
sion rate of HGD to adenocarcinoma is highly variable,
approximately 60% of patients with HGD will develop adeno-
carcinoma within five years,10 but 41% of these patients may
already have an in situ carcinoma at first diagnosis of HGD.11
Secondly, the patient benefits and cost effectiveness of the
current biopsy protocols have come into question because of
the low proportion of Barrett’s cases that progress to
adenocarcinoma.12–14 Finally, subjective grading by patholo-
gists results in intra and interobserver variation, and together
with biopsy sampling error can result in misdiagnosis.15 These
areas of concern clearly indicate a need for improved diagnos-
tic markers to classify patient risks for cancer development.
An understanding of the molecular mechanisms responsi-
ble for neoplastic progression is needed before genetic mark-
ers for risk assessment can be identified. Elucidation of such
underlying pathways requires characterisation of the genetic
alterations that accumulate at each stage of progression. How-
ever, the current chromosomal data available for Barrett’s
oesophagus lack consistency and implicate a wide variety of
genetic aberrations, possibly due to analysis mainly limited to
tissues from oesophageal adenocarcinoma (known to be
genetically unstable). Initial cytogenetic studies in our labora-
tory employed comparative genomic hybridisation (CGH) to
distinguish genetic alterations that may predict the malignant
potential of Barrett’s patients.16 Amplifications of chromo-
somes 4 and 8 were found in HGD but not in LGD or metapla-
sia. As CGH involves bulk analysis of sample tissues,
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aberrations must be present in a high proportion of cells
within the sample to be detected. Consequently, early changes
present in a low percentage of cells would be overlooked.
Hence in this study fluorescence in situ hybridisation (FISH),
which involves single cell analysis, was used. The sensitivity of
the FISH technique allows the detection of low frequency
aberrations such as those that may be present in premalignant
lesions.
In this study, Barrett’s epithelial cells were exfoliated with
endoscopic cytology brushes as this cell collection method
permitted the generation of interphase cell preparations (nec-
essary for cytogenetic investigation) from oesophageal tissues.
FISH was subsequently performed to determine at which pre-
malignant stage chromosome 4 and 8 aneuploidy and other
commonly detected aberrations in HGD and adenocarcinoma
first arise.
METHODS
Patients
Ethics approval was obtained for sample collection over a two
year period from consenting patients at Morriston District
General Hospital, Swansea, UK. Patients attended an endos-
copy clinic with a special interest in Barrett’s oesophagus,
which sought referrals for additional patients with dysplasia,
in particular HGD. Samples were in the form of cytology
brushings taken from 63 consecutive patients in total during
the sampling period: 28 with Barrett’s metaplasia, 28 with
dysplasia (20 LGD and eight HGD), and seven patients with
oesophageal adenocarcinoma. The study group male:female
ratio was 3:1, while the age range was 38–90 years (median
64). All the patients were Caucasian.
Endoscopic cytology brushings
Endoscopic cytology brushes were used to obtain two epithe-
lial samples from each patient: one was of normal proximal
squamous oesophageal tissue while the second was taken
within each patient’s Barrett’s segment. The brushes were
immediately placed into cold ETN buffer (0.1 M EDTA, 0.01 M
Tris-HCl, 0.02 M NaCl, pH 7) and agitated to generate a cell
suspension. Several biopsies were also taken from the Barrett’s
lesions (around the brushing site) for histological grading. As
brushing collects cells from a larger area than biopsies, they
are less likely to be subject to sampling error and so were
graded according to the most severe degree of dysplasia
recorded in the patient clinical notes.
Interphase cell preparations
The resultant cell suspension was washed three times by
centrifugation/re-suspension in ETN buffer. Following cleans-
ing, the cell pellet was resuspended in 500 µl of the buffer
solution, and Cytospin4 (ThermoShandon, Cheshire, UK) was
used to generate a single layer of interphase cells on
pre-cleaned glass slides. The cytodot cell densities were exam-
ined under a light microscope and their respective cell
suspensions were diluted/concentrated accordingly. Cell
preparations were fixed in 90% methanol at −20°C, left to air
dry, and then stored at −20°C. On average, 3–5 slides were
generated from each brushing.
Slide pretreatment
The interphase cell preparations were treated with 300 µl/ml
0.01 M HCl pepsin, pH 2.7–3 (Sigma, Dorset, UK) at 37°C for
seven minutes to remove cytoplasmic proteins, hence improv-
ing probe penetration.17 Two five minute washes in phosphate
buffered saline (PBS), followed by PBS/50 mM MgCl2 (both at
ambient temperature) arrested the enzymatic treatment, and
the slides were then dehydrated in an ethanol series to prepare
them for FISH.
FISH
Chromosome enumeration probes (CEP) for the centromeres
of chromosomes 4, 8, 20, and Y and locus specific identifier
(LSI) probes for p53, 13q14 (Rb locus), and dual probe 9p21/
CEP9 (p16 locus) were utilised (Vysis, Surrey, UK).
Due to the limited number of slides available for each sam-
ple, two probes were simultaneously hybridised in each reac-
tion. The dual probe 9p21/CEP9 was hybridised to one slide,
CEPs 8 and 20 were applied to a second slide, and the LSIp53
and 13q14 probes were hybridised to a third. Once scored, the
p53 and 13q14 probes were washed off the slide by rinsing in
1×phosphate buffered detergent at room temperature for five
minutes, followed by 1×standard saline citrate (SSC) at 90°C
for six minutes. To verify complete probe removal, these slides
were examined under an epifluorescence microscope prior to a
second round of probe hybridisation involving CEPs 4 and Y.
FISH was performed according to the manufacturer’s
instructions, with slight modifications. Briefly, 5 µl of probe
mixture (consisting of 3.5 µl hybridisation buffer, 0.5 µl each
probe, and water, to a 5 µl volume) were applied to each cyto-
dot. The sample and probe were co-denatured on a 75°C hot
plate for two minutes, and the slides were incubated for 30
minutes or 16 hours (for CEP or LSI probes, respectively) at
37°C. Following hybridisation, slides were washed in 0.4×SSC/
0.3% Nonidet P-40 at 73°C for two minutes, 2×SSC/0.1%
Nonidet P-40 at room temperature for 30 seconds, and allowed
to air dry. DAPI II 10 µl (Vysis, Surrey, UK) was subsequently
applied to counterstain the nuclei.
Signal visualisation
An Olympus BX50 epifluorescence microscope with single and
multiple bandpass filters was used to view the FISH slides. All
images were captured with a CCD camera coupled to the Mac-
Probe version 4.1 software (Applied Imaging, Newcastle Upon
Tyne, UK).
Scoring criteria
Slides were coded and 400 nuclei were analysed per cytodot.
Nuclei were only included in the analysis if they had at least
one signal from each probe utilised in order to avoid inclusion
of results caused by inadequate hybridisation. Overlapping,
damaged, or smeared nuclei and those covered with bacteria
were excluded from the analysis.
As all matched samples generated from the squamous
oesophageal tissues were normal, they were used as controls
to establish the background hybridisation variation. The cut
off levels for diagnosis of abnormal deletion/amplification
were therefore defined by the mean percentage of cells +3 SD
of the signal losses/gains displayed in the control samples
evaluated.18 19 As no signal gains were seen in the control sam-
ples with any of the probes utilised, all such amplifications
found within Barrett’s samples were considered aberrant. The
mean +3 SD percentage of nuclei with loss of one signal was
2.3%, 2.4%, 1.4%, 3.0%, 2.6%, 2.4%, 4.5%, and 3.0% for CEP4,
CEP8, CEP9, CEP20, CEPY, LSI 9p21, LSIp53, and LSI13q14,
respectively, and therefore signal loss was defined as abnormal
when higher than these cut off percentages.
Reproducibility
To verify protocol reproducibility, two slides from the same
brushing sample were hybridised with CEP8 and CEP20. In
addition, the whole battery of probes was applied to slides
originating from two separate brushings of the same Barrett’s
site. No significant difference was found between the data
generated (according to the χ2 test with 95% confidence
limits) thus demonstrating acceptable scoring reproducibility.
Histological correlation of brushings
Previous investigations have reported a positive correlation
between results from cytology brushings and biopsies taken
from the same Barrett’s segment.20 21 However, there are exist-
ing reports that have found brush cytology to be less sensitive
and specific for histological diagnosis.22 23 In this study, to cor-
relate the FISH data generated from the brushings with
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histology, biopsies taken from the brushed Barrett’s region of
five patients were halved. One half was sent to pathology for
grading (as metaplasia, indefinite for dysplasia, LGD, HGD, or
adenocarcinoma) by a panel of three histopathologists while
FISH using centromeric probes for chromosomes 4 and 8 was
performed on the other biopsy half. Chromosome 4 and/or 8
aneuploidy identified in the samples generated by the brush-
ings were also detected in 90% of the corresponding biopsies,
suggesting histological grading of biopsies reliably correlates
with data obtained from cytology brushes.
Table 1 Proportion of cells in each sample displaying significant signal amplifications or deletions of each fluorescence
in situ hybridisation probe utilised
Patient Pathology % 4L % 4G % 8L % 8G % 9L % 9G % p16L % p16G % RbL % RbG % p53L % p53G % 20L % 20G % YL
2 BM 3.3 3.5 3.7
3 BM 7.1 1.8 3.2 4.9
4 BM 22.8 1.3
5 BM 61.3 7.1 6.4
8 BM 4.5 1.0 2.8 1.5
11 BM
16 BM 4.7 2.8
19 BM 8.5 1.3 F
20 BM 5.6 4.5 3.8
33 BM 13.5 4.7 F
35 BM 9.7 F
46 BM 7.8 F
49 BM 9.0
51 BM 1.8 7.0
63 BM 14.5 4.2 19.8
73 BM 2.8 1.3 F
86 BM 25.3 3.8
95 BM 13.9 2.3 F
100 BM 37.3
105 BM 5.5 7.8
107 BM 3.3 5.5
109 BM 3.3 2.5 F
111 BM 4.5 3.8 F
117 BM 5.8 6.8 F
121 BM 19.8 2 5.3 52.3 33.3
127 BM 4.3 3.3 26.8
131 BM 8.8 3.5 12.5
135 BM 9.3 16.8 1.0
9 LGD 55.9 5.4 3.7 1.4
18 LGD 5.4 38.7
21 LGD 12.5 3.4 2.2 6.6 8.1
27 LGD 14.3
29 LGD 29.0 92.8 F
31 LGD 2.8
36 LGD 2.4 4.5 15.8 7.3
40 LGD 28.5
53 LGD 8.5 3.7 1.5 F
55 LGD 1.5 4.3 4.8 4.8
57 LGD 1.8 2.3 2.0 1.3 10.5
65 LGD 2.5 2.3 2.75 6
69 LGD 5.3 10.4 4.5 17.25
80 LGD 6.2 1.8 5.0
89 LGD 47.3 8.0 2.0 9.8 6.3
98 LGD 2.0 3.2 5.0
123 LGD 8.0 3.3
129 LGD 6.3 6.5 F
133 LGD 7.8 6.5
141 LGD 4.5 8.1 2.7 F
1 HGD 4.7 1.7 6.5 1 11.3
10 HGD 25.4 20.8 18.7 34.9 2.0 11.5 9.3 66.8
12 HGD 9.6 1.3 21.5 8.5 7.8
25 HGD 26.7 1.5 45.3 6.3 10.3
42 HGD 10.2 2.8 2.5 5.8 5.5
91 HGD 50.6 20.0 11.0 5.5 12 F
102 HGD 25.5 48.0 38.0 36.0 11.4
139 HGD 9.5 18.5 8.8 9.5 5.8 10.2
15 OA 32.4 2.7 3.0 1.5 4.3 5.8 7.7 4.2 F
17 OA 16.5 63.8 1.3 5.0 1.0 5.1 2.2 2.2 1.3 63.3
22 OA 54.0 12.0 2.2 8.5 10.0 4.6 3.0 2.3 7.8 1.4 15.8 10.3
48 OA 86.0 5.5 11.0 2.3 5.8 11.8 4.0 15.8 10.8 9.0 16.5 F
83 OA 65.8 5.3 7.0 28.0 8.0 4.0 43.3
88 OA 13.3 11.5 6.0 6.0 36.0 5.3 1.0 7
97 OA 11.0 8.5 6.8 2.3 14.3 1.3 4.0 6.0 1.0 7
G, signal gains; L, signal losses; F, female patients.
BM, metaplasia; LGD, low grade dysplasia; HGD, high grade dysplasia; OA, oesophageal adenocarcinoma.
All blank cells indicate samples that were normal (that is, did not display signal losses/gains above the cut off limits).
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RESULTS
The significant numerical abnormalities (involving the chro-
mosomes and loci examined) that were detected during this
analysis are catalogued in table 1, while fig 1 illustrates some
examples of these aberrant nuclei.
Chromosome 4
Chromosome 4 hyperploidy was the most prominent altera-
tion found in Barrett’s metaplasia with 89% of patients
displaying the aberration. As illustrated in fig 2, an increased
chromosome 4 copy number persisted into LGD and HGD
where it was present in 90% and 88% of cases, respectively, as
well as in all adenocarcinomas examined (fig 1A, B). The aver-
age percentage of cells displaying chromosome 4 hyperploidy
also increased with neoplastic progression from 12% (range
1–61%) in metaplasia to 14% (range 2–56%) in LGD, to 19%
(range 2–51%) and 40% (range 11–66%) of cells in HGD and
adenocarcinomas, respectively. Although most cells with this
aberration contained three copies of chromosome 4, up to five
copies were seen in some samples, but as they all displayed
either loss or a single copy of chromosome Y, the cells were
probably not polyploid, but aneuploid for chromosome 4.
Chromosome 8
Chromosome 8 hyperploidy was another predominant genetic
alteration present in 71% of metaplastic Barrett’s patients (fig
1E, F). This alteration was maintained during progression,
occurring in 75% of LGD and 100% of both HGD and
adenocarcinomas (fig 2). An increased chromosome 8 copy
number was detected in almost every sample that displayed
chromosome 4 hyperploidy (table 1) but chromosome 8 aneu-
ploidy generally developed in a lower proportion of cells in
each sample: 4% of cells in metaplastic samples (range
1–17%), 5% (range 2–10%) in LGD, 18% (range 1–48%) in
HGD, and 17% (range 3–64%) in oesophageal adenocarcino-
mas. Three copies was also the most predominant chromo-
some 8 complement found in these cells but up to six copies
were present in some. Cells generally displayed differing chro-
mosome 8 and 20 copy numbers, and so again these cells
appeared to be aneuploid and not polyploid.
Chromosome 20
Both losses and gains in chromosome 20 copy number were
evident during progression of Barrett’s oesophagus (fig 1E, F).
Fourteen per cent and 15% of metaplastic and LGD samples,
respectively, displayed a gain of chromosome 20 while 11%
and 10%, respectively, presented loss of the chromosome. In
HGD, chromosome 20 hyperploidy was far more prevalent,
occurring in 63% of samples compared with only 13% with
loss of the chromosome.
Chromosome Y
Only four males with metaplasia (21%) displayed loss of chro-
mosome Y but this increased to 38% in LGD, 71% in HGD, and
Figure 1 Examples of a variety of fluorescence in situ hybridisation (FISH) images obtained from Barrett’s interphase cell preparations.
(A) Two of three nuclei exhibiting chromosome 4 trisomy (cells originating from a female patient). (B) Male nucleus displaying chromosome 4
hyperploidy and loss of chromosome Y. (C) Nuclei all monoallelic for p16 (red) despite retaining two copies of chromosome 9 (green).
(D) Nuclei containing the normal compliment of the Rb gene (green signal) but were monoallelic for p53 (red). (E) Nucleus that was trisomic for
chromosome 20 (red) and tetrasomic for chromosome 8 (green signals). (F) Chromosome 8 hyperploidy (green) and chromosome 20
monosomy (red) are exhibited in this nucleus.
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finally to 100% in oesophageal adenocarcinomas bearing the
aberration (fig 2).
Tumour suppressor genes
Of the tumour suppressor genes analysed, hemizygous
deletion of p16 was the most common alteration (fig 1C), first
arising in metaplasia (7% of patients) and increasing in
prevalence with progression, as illustrated in fig 2. Loss of the
Rb tumour suppressor gene was a very rare event during pro-
gression of Barrett’s oesophagus, only being detected in a sin-
gle patient with HGD and in 2/7 of those with oesophageal
adenocarcinoma. p53 loss was also relatively uncommon in
the earlier stages of Barrett’s neoplastic progression. Only 7%
and 5% of metaplastic and LGD samples, respectively,
displayed losses of p53 but this increased to 38% of HGD
patients and 71% of adenocarcinomas.
DISCUSSION
We have shown that coupling brush cytology with interphase
FISH is an effective and sensitive way of analysing chromo-
somal alterations that arise during Barrett’s associated
neoplastic progression. FISH was selected for this purpose as
it involves single cell analysis and thus has the potential to
detect rare alterations such as those present in premalignant
lesions. Meanwhile, brush cytology exfoliates a large number
of epithelial cells over a broad area and hence is less prone to
sampling errors.
Our data verify previous CGH data produced by our group
that chromosomes 4 and 8 are frequently amplified in
Barrett’s oesophagus.16 The earliest and most prominent
alteration identified in this study was chromosome 4
hyperploidy which was present in 89% of metaplastic samples.
As this change is widespread in metaplasia, it may be involved
in the initiation of Barrett’s oesophagus. An increased
chromosome 4 copy number persisted in the majority of LGD
and HGD (90% and 88%, respectively) and was present in all
oesophageal adenocarcinomas examined. This suggests that
the aberration may also confer a cellular growth advantage
that is selected for in Barrett’s tissues and may consequently
be involved in promoting the progression of Barrett’s oesoph-
agus. Nevertheless, as only 10% of patients with Barrett’s
metaplasia progress to adenocarcinoma,24 chromosome 4
aneuploidy alone cannot be sufficient to drive neoplastic pro-
gression.
Investigations using CGH have reported both losses and
gains of chromosome 4 in oesophageal adenocarcinoma.16 25 26
However, data published by Persons and colleagues27 also
demonstrated the presence of chromosome 4 hyperploidy in
Barrett’s associated adenocarcinoma using FISH, although it
was not as prevalent as our findings. This discrepancy could be
due to the different sample preparations utilised. The investi-
gation by Persons et al was performed on paraffin embedded
tissue sections, which require considerably higher cut off per-
centages (to define signal losses/gains as abnormal) due to
nuclei truncation caused by the sectioning procedure. The
Persons et al study had to ignore alterations present in <25%
of cells, thus small abnormal clones would have been
overlooked. By performing FISH on a population of undam-
aged nuclei, we were able to identify low level alterations,
hence chromosome 4 hyperploidy was detected at a compara-
tively higher frequency. Although chromosome 4 contains cell
cycle control genes including CENPE (4q24-q25) and MAD2
(4q27) and oncogenes such as c-kit (4q12) and GRO2 (4q12-
q13), the target genes associated with chromosome 4
aneuploidy are unknown and require further study.
An increased chromosome 8 copy number was also identi-
fied in this study as an early abnormality (present in 71% of
metaplastic samples) that persisted into LGD (75%) and all
HGD and adenocarcinomas. Chromosome 8 hyperploidy
occurred in a lower proportion of cells compared with
chromosome 4 hyperploidy, but its prevalence suggests this
aberration, in conjunction with other genetic alterations, may
result in a phenotype that promotes neoplastic progression.
Previously, several investigations have detected chromosome 8
amplifications in a high proportion of oesophageal
adenocarcinomas25 26 28 and one study has identified the
alteration in premalignant Barrett’s tissue.29 The oncogene
c-myc (8q24) has been implicated as a potential target for this
amplification by these previous analyses and a recent investi-
gation has further highlighted its amplified expression in
Barrett’s metaplasia and adenocarcinoma.30
Of the tumour suppressor genes examined, hemizygous
deletion of p16 (9p21) was the most common, first arising in
a small proportion of the metaplastic samples examined and
then increasing in prevalence with progression. There was a
very low rate of p53 deletion in premalignant Barrett’s
oesophagus, while Rb loss was only found in a single HGD and
two oesophageal adenocarcinoma samples, indicating that
deletion of these two latter genes are not very important
events in the progression of Barrett’s oesophagus. Other
means of p53 and Rb inactivation (for example, mutation, CpG
methylation) may play more significant roles.31 32
A general increase in the percentage of aberrant nuclei per
sample can be seen as metaplasia progresses through dyspla-
sia to adenocarcinoma. When examining the number of
alterations that are present in samples at each stage of
progression, it is clear that metaplasia displays the least
number of abnormalities while adenocarcinomas exhibit the
widest range. This observation, previously noted in our
laboratory16 and by several others,25 29 33 demonstrates the
increasing genetic instability that accumulates and may be
responsible for driving neoplastic progression in Barrett’s
oesophagus. The proportion of cells per sample harbouring a
particular abnormality also increased with neoplastic progres-
sion. For example, the average percentage of cells per sample
displaying amplifications of chromosome 4 copy number
gradually increased from 12% in metaplasias to 40% in adeno-
carcinoma samples, therefore providing further evidence for
the role of clonal selection and expansion in the progression of
Barrett’s oesophagus.34
Figure 2 Percentage of metaplastic, dysplastic, and oesophageal
adenocarcinoma samples that had chromosome 4/8 hyperploidy,
monoallelic p16, or lacked their Y chromosome. The results are
derived from analysis of 28 patients with metaplasia (BM), 20 with
low grade dysplasia (LGD), eight with high grade dysplasia (HGD),
and seven with oesophageal adenocarcinoma (OA).
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In conclusion, this study has identified genetic instability in
Barrett’s metaplastic tissues with chromosome 4 and 8 aneu-
ploidy representing the most prominent and earliest altera-
tions. The implications of these alterations are as yet unclear
but as they are so widespread in all of the premalignant Bar-
rett’s stages, it is possible that the amplification points to key
genes on these chromosomes that may be mechanistically
involved in the initiation and progression of the lesion. This
study has also demonstrated brush cytology coupled to FISH
analysis as a suitable technique for identification of early
genetic abnormalities. Although follow up investigation of
these patients has yet to be performed, this approach may
prove to be a useful surveillance tool for identification of aber-
rations in premalignant lesions that increase a patient’s
neoplastic potential.
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